<DOC>
	<DOCNO>NCT00005981</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient metastatic colorectal carcinoma treat O6-benzylguanine carmustine . - Evaluate tumor tissue biochemical immunohistochemical predictor response patient treat regimen . - Correlate carcinoembryonic antigen level peripheral blood response patient treat regimen . OUTLINE : This multicenter study . Patients receive O6-benzylguanine ( BG ) IV 1 hour carmustine IV 1 hour ( begin 1 hour completion BG infusion ) day 1 . Treatment continue every 6 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 19-36 patient accrue study within 1.7-3 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic colorectal carcinoma Bidimensionally measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 4,000/mm^3 Granulocyte count least 1,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin great 8 g/dL Hepatic : Bilirubin great 1.2 mg/dL AST ALT less 2.5 time upper limit normal ( ULN ) PT great ULN ( anticoagulation therapy ) Renal : Creatinine great 1.5 mg/dL Creatine clearance great 60 mL/min Pulmonary : DLCO least 60 % Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study No concurrent active malignancy Prior malignancy presume cured allow No concurrent uncontrolled severe medical problem would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 month since prior adjuvant chemotherapy without disease recurrence No 1 prior chemotherapy regimen metastatic disease Endocrine therapy : Not specify Radiotherapy : Prior adjuvant radiotherapy allow No prior radiotherapy 25 % total bone marrow Surgery : Not specify Other : No prior therapy advance disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>